Overview

R(+)PPX High Dose Treatment of ALS

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bennett, James P., Jr., M.D., Ph.D.

Treatments:

Pramipexole